Literature DB >> 23542399

Organ Specific Tumor Markers: What's New?

Kannan Vaidyanathan1, D M Vasudevan.   

Abstract

Tumor markers are molecules produced in the body in response to cancer. An ideal tumor marker should have high sensitivity and specificity, should be cheap, and should be easily detected in body fluids. Identification of novel markers is important and it is expected that with the advent of newer technologies, more reliable markers will be discovered. This review discusses the currently available tumor markers for different malignancies.

Entities:  

Keywords:  Immunohistochemical markers; Molecular markers; Proteomic markers

Year:  2011        PMID： 23542399      PMCID： PMC3358375          DOI： 10.1007/s12291-011-0173-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN： 0970-1915


  71 in total

Review 1.  Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry.

Authors:  E D Hsi; S Yegappan
Journal:  Adv Anat Pathol       Date:  2001-07       Impact factor: 3.875

Review 2.  Translating basic research in cancer patient care.

Authors:  Marcello Maugeri-Saccà; Ruggero De Maria
Journal:  Ann Ist Super Sanita       Date:  2011       Impact factor: 1.663

3.  Inhibin-α subunit expression in uterine endometrioid adenocarcinomas and endometrial cancer cell lines: a potential prognostic factor.

Authors:  Ioannis Mylonas
Journal:  Int J Mol Med       Date:  2010-12-21       Impact factor: 4.101

4.  Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lymphoma cases.

Authors:  Abdullah Maha; Gin Gin Gan; Chong-Lek Koh
Journal:  Hematology       Date:  2010-12       Impact factor: 2.269

Review 5.  Pancreatic cancer in 2010: new insights for early intervention and detection.

Authors:  Eithne Costello; John P Neoptolemos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 6.  Cancer biomarkers - current perspectives.

Authors:  Anant Narayan Bhatt; Rohit Mathur; Abdullah Farooque; Amit Verma; B S Dwarakanath
Journal:  Indian J Med Res       Date:  2010-08       Impact factor: 2.375

Review 7.  Molecular diagnostics of thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Arch Pathol Lab Med       Date:  2011-05       Impact factor: 5.534

8.  Her2 expression in prostatic cancer: a comparison with mammary carcinoma.

Authors:  Merce Jorda; Azordes Morales; Zeina Ghorab; Gustavo Fernandez; Mehrdad Nadji; Norman Block
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

9.  Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.

Authors:  R C Bast; T L Klug; E Schaetzl; P Lavin; J M Niloff; T F Greber; V R Zurawski; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1984-07-01       Impact factor: 8.661

10.  Expression of HER2 in colorectal cancer does not correlate with prognosis.

Authors:  Wiesław Janusz Kruszewski; Robert Rzepko; Maciej Ciesielski; Jarosław Szefel; Jacek Zieliński; Mariusz Szajewski; Wojciech Jasiński; Krzysztof Kawecki; Janusz Wojtacki
Journal:  Dis Markers       Date:  2010       Impact factor: 3.434
View more
  4 in total

Review 1.  Interfacial interactions of SERS-active noble metal nanostructures with functional ligands for diagnostic analysis of protein cancer markers.

Authors:  Han-Jung Ryu; Won Kyu Lee; Yoon Hyuck Kim; Jae-Seung Lee
Journal:  Mikrochim Acta       Date:  2021-04-12       Impact factor: 5.833

2.  Detection of a soluble form of CD109 in serum of CD109 transgenic and tumor xenografted mice.

Authors:  Hiroki Sakakura; Yoshiki Murakumo; Shinji Mii; Sumitaka Hagiwara; Takuya Kato; Masato Asai; Akiyoshi Hoshino; Noriyuki Yamamoto; Sayaka Sobue; Masatoshi Ichihara; Minoru Ueda; Masahide Takahashi
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

3.  Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.

Authors:  Lisa Bartmann; David Schumacher; Saskia von Stillfried; Marieke Sternkopf; Setareh Alampour-Rajabi; Marc A M J van Zandvoort; Fabian Kiessling; Zhuojun Wu
Journal:  Front Pharmacol       Date:  2019-02-06       Impact factor: 5.810

4.  Tandem microfluidic chip isolation of prostate and breast cancer cells from simulated liquid biopsies using CD71 as an affinity ligand.

Authors:  Bhagya Wickramaratne; Dimitri Pappas
Journal:  RSC Adv       Date:  2020-09-02       Impact factor: 4.036
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.